FDA approves Retatrutide this year priced at 4.9% on Polymarket, up 1.6 points, on $597K traded

A Polymarket contract on whether the FDA will approve Retatrutide this year was priced at a 4.9% implied probability in the supplied Oct 30, 2026 · 2:39 AM ET snapshot. The probability was up 1.6 percentage points, with $597K traded.

The increase leaves approval this year priced as a low-probability outcome. The contract concerns whether approval will happen; the quoted price is not evidence that the FDA has approved Retatrutide.

No fresh catalyst identified

The accompanying news summary reported no significant new platform headline in the preceding 30 minutes. It did not identify fresh regulatory reporting that explained the contract’s move, so the supplied material does not establish a news catalyst.

According to predictionbubbles.net, its market dashboard republishes prices from Polymarket and Kalshi every 15 minutes, while trading on the venues continues between updates. The supplied page describes that methodology but does not include a Retatrutide-specific listing, price history or resolution criteria, limiting independent verification of the headline snapshot.

What it means for prediction markets

• A move higher, but still low odds: The 1.6-percentage-point increase brought the quoted probability to 4.9%, not close to an even chance.
• Volume is not confirmation: The $597K traded describes market activity, not evidence of an FDA decision.
• Timing and rules matter: The snapshot may differ from subsequent prices, and the supplied material does not specify the contract’s exact approval requirements or resolution process.